Home Product Updates

Product Updates

Product updates , including portfolio re-optimisation

income plus max

You wanted higher payouts and growth. Meet Income+ Max.

We asked investors what matters most in an income portfolio. Here's what they told us, and how it shaped Income+ Max, which targets 8-10% p.a. in monthly payouts.

Introducing Income+ Max

We are excited to launch Income+ Max, a multi-asset income strategy with target payouts of 8%-10% p.a.
Syfe Core

Core Portfolios Update: Powering Ahead with UCITS Upgrades

Core has been upgraded with a significant increase in UCITS coverage. Combined with fee optimisations, 94% of Core now invests through the most cost-effective vehicles available.

Income+ Defensive & Enhance: Optimising Returns, Delivering Regular Income

The current economic climate have brought fixed income strategies into spotlight again. Here's how Income+ comes into play.
Cash+ Enhanced Syfe

Introducing Syfe Cash+ Enhanced: A Home for Your “Soon” Money

Cash+ Enhanced is built to bridge the gap in growing money you don't need in the next year or two, with target yields of up to 3.0% p.a. and no lock-ins.

Syfe Managed Portfolio Performance Q1 2026: In a World of Wars, Focus on Fundamentals

Syfe portfolios stayed resilient during the Iran War sell-off, outperforming through diversification, strong yields, and a more selective strategy.

The Age of “Smart” Alpha: Why Investors Need a New Strategy

With markets on sky-high valuations and returns extremely concentrated in a few megacap companies, a new, smarter solution is needed for those who want to stay invested.

A Comprehensive Guide to Syfe’s Cash+ Guaranteed

In today’s evolving financial landscape, traditional saving methods like fixed deposits are no longer the only option for conservative investors seeking both stability and returns on their cash. There is an increasing appetite for investment alternatives that offer stable returns while still providing safety and liquidity.  This is where Syfe’s...

Syfe Core Portfolios Monthly Update: November 2025 Outperformance

November saw a pause in global markets after a strong run earlier in the year. Against this backdrop, our portfolios generally outperformed their benchmarks.

Healthcare Innovation Portfolio: Balancing Exposure and Capturing Upsides

Syfe's Healthcare Innovation thematic portfolio invests in companies at the cutting edge of genomics, biotechnology, pharmaceuticals, and more.